AstraZeneca warns Europe drug launches may hinge on higher pricing

Traders Union
All News
Financial News
AstraZeneca warns on EU drug pricing

Highlights

AstraZeneca CEO Sir Pascal Soriot warns new drug launches in the UK and Europe may be delayed without higher prices for innovative medicines.
Most Favored Nation agreements in the U.S., which tie drug prices to lower European levels, are causing companies to reconsider launches in Europe due to pricing knock-on effects.
AstraZeneca affirms long-term UK commitment with a FTSE listing, Cambridge R&D expansion (£300 million investment in April), and new Macclesfield laboratory plans despite only 2% of revenue from the UK.

Pricing pressure reshapes launch strategy

As reported by Financial Times, chief executive Sir Pascal Soriot says the Anglo-Swedish drugmaker may have no choice but to hold back new medicines in the UK and Europe if it cannot secure better prices for innovative treatments.

He argues that the group must balance patient access with shareholder returns and future research spending, especially after agreements with the Trump administration require lower prices for some U.S. medicines. Those arrangements, known as Most Favored Nation agreements, are designed to ensure certain drug prices in the U.S. do not exceed those in Europe, Japan and Canada.

Soriot says the structure of those deals is already pushing companies to reconsider whether to launch medicines in Europe, because lower European prices can feed back into U.S. pricing. He adds that Europe, including the UK, spends about 0.4% of GDP on innovative medicines, compared with about 0.8% in the U.S.

UK commitment and broader industry impact

AstraZeneca draws about 45% of its revenue from the U.S., while the UK accounts for about 2%, a level Soriot says is similar to France and Spain. In that context, he questions why a company would risk a far larger U.S. revenue base if it cannot obtain what it sees as a reasonable price in smaller European markets.

The UK has already committed to raising NHS medicines spending, but funding sources remain unclear. Soriot describes that move as progress, while saying it still does not go far enough to support access to innovative drugs.

His comments come after AstraZeneca’s direct listing in New York, completed in February, which has prompted speculation about its long-term London market presence. Soriot rejects that interpretation and says the company remains committed to the UK, pointing to its FTSE index presence, a major R&D site in Cambridge, a £300 million investment announced in April to complete the expansion of that facility, and plans for a new laboratory in Macclesfield.

Our earlier report on OpenAI’s talks with the Trump administration covered discussions about a potential arrangement in which the company could donate equity to the U.S. government, tied to a proposed “Public Wealth Fund.” We noted this was unfolding alongside broader federal moves to take stakes in strategic tech firms and tighten the government’s role in AI—signaling a more interventionist policy backdrop as major companies weigh funding, regulation, and market strategy.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.